



## H.C. Wainwright 23rd Annual Global Investment Conference

13 – 15 September 2021

# Notice: Forward looking statements

The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by the Company and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by the Company. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

# Our Overview

01

## Our Vision & Brand Pillars

2021 Overview  
Where are we now

02

## Our Markets

Prioritising the market entry strategy by region

03

## Our Acquisition

EasyDNA - Building our Direct-to-Consumer growth pathway

04

## Our Channels & Divisions

Focused on three distinct and target routes to market

05

## Our Portfolio & Innovation

Executing through cutting edge innovation and 'game changing' partnerships

06

## Our Capabilities

Aligning our internal capability aligned to execution

# Unlocking personalised preventative health

Significant progress has been made in understanding the role of hereditary risk in chronic disease, however, many chronic conditions cannot be predicted by this risk alone.

We're transforming the conversation. Transitioning from a one-size-fits-all model to personalised, predictive health assessment – where each person has the information they need to manage their health according to their own risk.

Backed by over 20 years of experience, our doctors, scientists and technicians are translating genetic information into multi-tests that uniquely combine genetic and clinical risk models to predict risk of chronic diseases before onset.

We're empowering physicians to improve health outcomes for people around the world. Tracking disease to its source. Enabling a new era of personalised medicine.



# geneType's brand evolution reflects its commitment to personalised, preventative health care



## Unequalled experience

Scientific team leveraging their extensive research track record in breast and colorectal to expand our medical-grade genetic test portfolio into further cancers and chronic conditions



## Leading integrated technology

The sophisticated integration of genomic and clinical risk factors deliver the most complete risk assessments for serious diseases in the world



## Relentless innovation

Accelerating the world's transition to personalised, preventative health care by converting genetic data into actionable solutions for consumers and doctors



## Setting new standards

Setting clinical, safety and ethical standards to ensure the best health outcomes

# Our 2021 Snapshot



## Signed multi-year distribution agreement

License and distribution agreement for COVID-19 Risk Test with IBX for minimum of US\$2.9 million over 3 years to maintain exclusivity  
Launched CIT in USA & AUS for other tests<sup>1</sup>



## Focused on commercialisation of R&D

Over a decade of R&D translating to commercial launch of geneType for Breast Cancer, Colorectal Cancer & COVID-19



## On track to launch new Multi-test

New Multi-test development on track for serious disease risk including major oncological, metabolic and degenerative diseases - covering up to 70% of mortalities and morbidities



## Acquired revenue generating platform

Acquired EasyDNA for US\$4m in cash and script<sup>2</sup> providing global platform with US\$4.63m in unaudited revenue in CY20



## Solid balance sheet

A\$17.6 million pro forma cash balance following settlement of EasyDNA, providing a 24-month runway



## Robust patent portfolio & clinical credibility

17 patents granted and 9 patent families pending multiple peer-reviewed publications and four collaborations with prestigious academic and medical establishments

1. geneType for Breast Cancer and Colorectal Cancer certified for sale via online sales platform.  
2. Runway based on current cash projections and including the acquisition of EasyDNA



01

Our Vision &  
Brand Pillars

02

Our Markets

03

Our Acquisition

04

Our Channels &  
Divisions

05

Our Portfolio &  
Innovation

06

Our Capabilities

# Our Markets and Collaborators

## United States

geneType® Polygenic Risk Score (PRS) tests for breast, colorectal cancer and COVID-19 Risk Test available through **CLIA** Certified “High Complexity” Laboratories.

Further products expected to be submitted in next 12 months

## Europe & UK

Commencing CE certification enabling EU launch of Novel genetic risk test in CY2021

EasyDNA available multiple EU countries and UK

## Asia

(Inc. SEA, China and India)

H2 CY2021 to commence a scoping and Prioritising a market entry strategy into Asia

EasyDNA available in multiple countries across SEA

## Australia & New Zealand

Certification by Australian regulators **NATA**, to sell into the Australian market

Two products<sup>1</sup> currently certified and further products expected to be submitted in next 12 months



<sup>1</sup> GeneType for Breast Cancer and Colorectal Cancer certified for sale via online sales platform.



# A strategy to own the personalised, preventative health testing market

## Brand Recognition and Advocacy



### Thought leadership

Demonstrating our leadership by informing the conversation on personalised, preventative health care



### Seeded content

Amplifying our impact by starting and informing conversations in key consumer and clinical channels



### geneType advocacy

Building a group of clinicians and consumers willing to share with their colleagues and friends their experience with geneType

## Commercialization and Branding



### Sales & marketing

Core set of sales and marketing tactics and assets tailored by therapeutic area, and adapted by geography



### Medical education


Motivating trial and purchase with medical education for clinicians and consumers




### geneType Hubs

Empowering clinicians to use geneType. Their clinic becomes a geneType Hub that taps into a GP referral network and reinforcing their leadership in personalised, preventative health care


# A cutting-edge geneType brand set for relaunch



Mobile



Digital



Education



01

Our Vision &  
Brand Pillars

02

Our Markets

03

Our Acquisition

04

Our Channels &  
Divisions

05

Our Portfolio &  
Innovation

06

Our Capabilities



# EasyDNA – Acquisition of DTC Platform


- Acquired EasyDNA in August 2021 for US\$4 million
- Current revenues of US\$4.63 million through retail sales of its at-home DNA tests
- Agreements with 12 laboratories in North America, AsiaPac and Europe
- A platform to launch the geneType Multi Test and portfolio of serious disease tests across 40 countries\*




easyDNA®

# EasyDNA – Establishing our Lifestyle Division

- Headed by Kevin Camilleri
- EasyDNA currently sells paternity, oncology and health and wellbeing genomics-based tests
- This acquisition provides Genetic Technologies the foundation to grow in **40 countries**
- Expand the health related tests with an extensive DTC marketplace





01

Our Vision &  
Brand Pillars

02

Our Markets

03

Our Acquisition

04

Our Channels &  
Divisions

05

Our Portfolio &  
Innovation

06

Our Capabilities



# Our Pathways

## Medical – Business to Business (B2B)

A communication and execution plan curated for

Payers / Insurers

Primary Care Physicians

Specialists

Surgeons

Allied Health



Certifying reimbursable germline testing platform

BRCA test

LYNCH Syndrome test

*(More to follow)\**



## Consumer initiated testing (CIT) with medical supervision

Launched US and Australia CIT platforms in 2020 with medical supervision with:

InTeleLabs in the US

Phenix Health in Australia



Current products include:

*geneType for Breast Cancer*

*geneType for Colorectal Cancer*

AUD\$349 / US\$249 per test



## Direct to consumer testing (DTC) with no medical supervision

Recent Acquisition announced for EasyDNA



Leverage for paternity, ancestry, gut microbiome testing and non-medical related genomic tests

[www.Easydna.com](http://www.Easydna.com)



Provides Genetic Technologies the foundation to grow in **40 countries**


Agreements with **12 laboratories in North America, AsiaPac and Europe**



# Our Divisions

 Emerging divisions


 Existing divisions



**NEW – Universal collection test kit to support Multi Test Launch**







01

Our Vision &  
Brand Pillars

02

Our Markets

03

Our Acquisition

04


Our Channels &  
Divisions

05

Our Portfolio &  
Innovation

06


Our Capabilities



# Our Innovation


geneType integrates genetic risk and clinical risk to better stratify individual risk. Patients with potentially high risk may exceed actionable clinical guidelines 10 – 15 years earlier than those with low risk <sup>1,2,3</sup>

Breast Cancer (BC)<sup>1</sup>




↑ Low polygenic risk score  
↑ High polygenic risk score

Colorectal Cancer (CRC)<sup>2</sup>



Chronic Heart Disease (CHD)<sup>3</sup>



geneType detects patients at an actionable risk of serious disease  
10 – 15 years earlier than currently possible  
Potentially significantly improving patient outcomes and health economics

# Our Portfolio – Driving Growth

CIT Platform in AUS and USA selling BRC and CRC




Moderate Revenue Expectations Q2 CY 2021

IBX COVID Risk Test released for sale May 31, 2021



Revenue Commenced Q2 CY 2021

100% Germline + PRS test for Breast Cancer and CRC to launch in AU & USA



Expanding into reimbursable space

Commercially Available Q4 CY 2021

Multi Test to provide risk assessment for >70% of all morbidities to launch



Market Release to include up to 70% of morbidity:

- Breast Cancer
- Colorectal Cancer
- Cardiovascular Disease
- Type 2 Diabetes
- Melanoma
- Prostate Cancer

Commercially Available Q4 CY 2021

December 2020

April 2021

July 2021

H2 2021



# Significant market opportunity

To provide predictive, pre-symptomatic testing to inform lifestyle choices and healthcare discussions  
Guideline driven, reimbursable for inherited and non inherited disease

## Near Term Addressable Market

$$\begin{array}{c}
 \text{281,550}^5 \\
 \text{Diagnosis of breast cancer} \\
 \text{annually in United States} \\
 \text{(19,974 cases diagnosed annually in Australia}^3\text{)}
 \end{array}
 +
 \begin{array}{c}
 \text{1}^{\text{st}} \text{ degree} \\
 \text{relatives}
 \end{array}
 =$$

$$\begin{array}{c}
 \text{149,500}^6 \\
 \text{Diagnosis of colorectal cancer} \\
 \text{annually in United States} \\
 \text{(15,494 cases diagnosed annually in Australia}^4\text{)}
 \end{array}
 +
 \begin{array}{c}
 \text{1}^{\text{st}} \text{ degree} \\
 \text{relatives}
 \end{array}
 =$$

## GTG Target Market for

### BRCA Panel + Breast Cancer PRS

#### Testing

providing up to 100% genetic  
risk cover screening



## GTG Target Market for

### LYNCH Syndrome Panel + Colorectal

#### Cancer PRS Testing

providing up to 100% genetic  
risk cover screening



**Global Predictive Genetic Testing Market anticipated to exceed \$28bn by 2026<sup>1</sup>**

1. Genetic Testing Market Size By Test Type (Predictive Testing, Carrier Testing, Prenatal and New-born Testing, Diagnostic Testing, Pharmacogenomic Testing, Nutrigenomic Testing), By Application (Cancer, Genetic Disease, Cardiovascular Disease), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2020 – 2026; Published Date: Feb 2020; Authors: Sumant Ugalmugle, Rupali Swain
2. PRS = Polygenic Risk Score
3. <https://www.canceraustralia.gov.au/affected-cancer/cancer-types/breast-cancer/breast-cancer-australia-statistics>
4. <https://www.canceraustralia.gov.au/affected-cancer/cancer-types/bowel-cancer/bowel-cancer-colorectal-cancer-australia-statistics>
5. <https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html>
6. <https://www.cancer.net/cancer-types/colorectal-cancer/statistics>

# Our Innovation - Multi Test

A companion diagnostic PRS to help identify risk of serious disease for up to 70% of Mortalities and Morbidities  
Committed to continually invest in developing multi population testing solutions

 Phase 1 Launch <sup>2</sup>

 Phase 2 Launch <sup>3</sup>

## Oncology

Breast Cancer  
Colorectal Cancer  
Prostate Cancer  
Melanoma  
Pancreatic Cancer  
Ovarian Cancer

1

## Cardiovascular

Atrial Fibrillation  
Coronary Artery Disease

2

## Metabolic

Type 2 Diabetes

3

## Mental Health

Taliz

4

GeneType Multi-test to include  
>70% of mortality & morbidity



NEW Universal sample collection kit with  
TGA, FDA and EU regulatory approval<sup>1</sup>

1. TGA, FDA and EU regulatory approval granted to the sponsor, DNA Genotek  
2. Commercial availability expected Q4 CY2021  
3. Commercial availability expected Q1 CY2022



01

Our Vision &  
Brand Pillars

02

Our Markets

03

Our Acquisition

04

Our Channels &  
Divisions

05


Our Portfolio &  
Innovation


06

Our Capabilities



# Our Capability





01

**Our Vision &  
Brand Pillars**

02

**Our Markets**

**Targeted and  
deliberate**

03

**Our Acquisition**

**Positioned for  
growth**

04

**Our Channels &  
Divisions**

**Focused and  
distinct**

05


**Our Portfolio &  
Innovation**

**Cutting edge  
innovation**

06

**Our Capabilities**

**Aligned to  
execute**







Thank you



# Appendices

# Our Intellectual Property

## 7 Patents granted in the US

- Patent 11,031,098, Computer systems and methods for genomic analysis
- Patent 10,683,549, Methods for assessing risk of developing breast cancer
- Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering three of the core genetic markers included in the BREVAGenplus® risk assessment test
- Patent No. 7,127,355 offering broad protection re: methods of genetic analysis (the concept of combining clinical risk assessment with genetic risk factors to improve predictability over clinical risk assessment alone)
- Patent No. 6,969,589 covering the identification of informative SNPs

## 5 Patents granted in China

- Patent Nos. 200680051710.0; 201310524782.4; 201310524916.2 and 201310524765.0 “Markers for Breast Cancer”
- Patent No. 201080033130.5 Methods for Breast Cancer Risk Assessment

## 5 Patents granted in Hong Kong

- Patent Nos. 09101235.4; 12112875.1; 12112368.5 and 12112874.2 “Markers for Breast Cancer”
- Patent No. 12109000.5 Methods for Breast Cancer Risk Assessment

## 9 Patent families pending

- Methods for breast cancer risk assessment
- Methods for assessing risk of developing breast cancer
- Improved methods for assessing risk of developing breast cancer
- Markers for breast cancer
- Methods for genetic analysis
- Methods for genomic analysis
- Methods for assessing risk of developing colorectal cancer
- Methods of assessing risk developing a disease
- Methods for assessing risk of developing a severe response to coronavirus infection

# Board and Management: Sales and Scientific expertise leading GTG



**Mr. Peter Rubinstein**

BEC, LLB  
Chairman - Non – Executive  
Director



**Dr. Lindsay Wakefield**

MBBS  
Non – Executive Director



**Mr Nick Burrows**

B.Com, FAICD, FCA,  
FGIA, FTIA, F Fin  
Non – Executive Director



**Simon Morriss**

GAICD  
Chief Executive Officer



**Dr. Jerzy “George” Muchnicki**

MBBS  
Executive Director & Chief  
Medical Officer



**Erika Spaeth**

PhD  
Director of Clinical Affairs &  
Medical Education



**Richard Allman**

BSc, PhD  
Chief Scientific Officer



**Mike Tonroe**

BSc, FCA, MAICD  
Chief Financial Officer



**Carl Stubbings**

Chief Commercial Officer

# Strong Scientific Leadership: Advisory Board



**Professor Jon Emery**

MBBCh MA DPhil FRACGP MRCGP  
Research & Education Lead, Primary Care  
Integration, Victorian Comprehensive  
Cancer Centre Herman Chair of Primary  
Care Cancer Research, University of  
Melbourne



**Professor Finlay Macrae AO**

MBBS, MD, FRACP, FRCP, AGAF MWGO is  
Principal Fellow and Professor, Department  
of Medicine, University of Melbourne, and  
Head of Colorectal Medicine and Genetics,  
The Royal Melbourne Hospital




**Ora K. Gordon, M.D.**

MD, MS, FACMG  
Regional Medical Director, Center for  
Clinical Genetics & Genomics. Clinical  
Director, PSJH Population Health Genomics  
Program. Chair, Integrated Network Cancer  
Program, Professor of Genetics, St John  
Cancer Institute

# Corporate Overview

Top 50 share registry breakdown



## Dual Listed on the ASX and Nasdaq

### Financial Information

Share price (AUD) as at 7 September 2021 0.8c

ADR price (USD) as at 7 September 2021 \$3.37

Ord Share on Issue (M) 9,226

ASX 52-week trading (low/high) 0.6/1.4c

Nasdaq 52-week trading (low/high) \$2.77/8.18

**Market Cap (A\$/US\$M) 73.81/51.82**

Cash (30 June 2021) A\$20.9m

Debt (30 June 2021) nil

# Defined Terms

**Common Complex Diseases (CCP)** – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease.

**Polygenic risk score** - a number associated with one's disease risk based on the aggregated effects of individual risk variants through a multiplicative algorithm.

**Variant** - Single Nucleotide polymorphism (SNP), an alteration in DNA that may be a common or rare event.

**Genomic** - pertaining to function of genetics from structure to relationship between genetic events.

**Genetic** - pertaining to a gene.

**GWAS** - genome-wide association studies are large population level studies which enable scientists to identify genes and genetic markers involved in human disease. This method searches the genome for SNPs that occur more frequently in people with a particular disease than in people without the disease. Each study can look at hundreds or many thousands of SNPs at the same time. Researchers use data from this type of study to pinpoint genetic variations that may contribute to a person's risk of developing a certain disease.

**SNP** - Single nucleotide polymorphisms, frequently called SNPs (pronounced "snips"), are the most common type of genetic variation among people. Each SNP represents a difference in a single DNA building block, called a nucleotide. For example, a SNP may replace the nucleotide cytosine (C) with the nucleotide thymine (T) in a certain stretch of DNA.

**Serious Disease Risk (SDR)** - Risk associated with acquiring COVID-19 and requiring hospitalisation with its associated morbidities and mortalities.

**Germline Testing** – Germline testing is done on cells that do not have cancer. It is done to see if a person has a gene mutation that is known to increase the risk of developing cancers and other health problems. This test uses cells (such as blood or skin cells) that do not have any cancer cells. Germline mutations can sometimes be passed down from parents.

**Clinical Laboratory Improvement Amendments (CLIA)** - Regulates laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing

**National Association of Testing Authorities (NATA)** - the authority responsible for the accreditation of laboratories, inspection bodies, calibration services, producers of certified reference materials and proficiency testing scheme providers throughout Australia. It is also Australia's compliance monitoring authority for the OECD Principles of GLP. NATA provides independent assurance of technical competence through a proven network of best practice industry experts for customers who require confidence in the delivery of their products and services.

**Next Generation Sequencing (NGS)** – Next-generation sequencing (NGS), also known as high-throughput sequencing, is the catch-all term used to describe a number of different modern sequencing technologies. These technologies allow for sequencing of DNA and RNA much more quickly and cheaply than the previously used Sanger sequencing, and as such revolutionised the study of genomics and molecular biology.

**Laboratory Developed Tests (LDT)** – A type of in vitro diagnostic test that is designed, manufactured and used within a single laboratory.

**Consumer Initiated Tests (CIT)** - laboratory testing that is initiated by the consumer without a physician order but reviewed and communicated back to the consumer via a physician.

**Direct to Consumer (DTC)** – laboratory testing that is initiated by the consumer without a physician order. The results are reported back directly to the consumer.